In ₹ Crore except Per Share Latest Annual	IPCALAB FY26	TORNTPHARM FY26	ALKEM FY26	JBCHEPHARM FY26	Peer Average
Valuation — at last close
P/E	42.92×	71.29×	◆ 26.34×	—	48.81× -12%
P/B	6.07×	18.39×	◆ 4.39×	—	11.39× -47%
EV/EBITDA	25.24×	38.65×	◆ 20.06×	—	29.36× -14%
Market Cap	₹48,977 Cr	₹1.54L Cr	₹60,612 Cr	—	₹1.07L Cr -54%
Growth
Revenue CAGR 3Y	◆ 15.60%	13.27%	8.25%	9.61%	10.38% +50%
Revenue CAGR 5Y	12.22%	11.80%	10.09%	◆ 15.22%	12.37% -1%
Net Income CAGR 3Y	◆ 35.20%	19.75%	32.67%	20.06%	24.16% +46%
Revenue YoY (latest Q)	20.76%	◆ 50.79%	10.95%	-4.77%	18.99% +9%
Net Income YoY (latest Q)	◆ 82.18%	-9.64%	-22.00%	-30.42%	-20.69% +497%
Profitability
EBITDA Margin	20.51%	◆ 32.61%	20.43%	26.70%	26.58% -23%
Net Income Margin	12.27%	15.29%	15.98%	◆ 17.10%	16.12% -24%
Return on Common Equity	15.20%	◆ 27.07%	17.84%	18.69%	21.20% -28%
Return on Capital Employed	16.05%	14.88%	17.59%	◆ 23.07%	18.51% -13%
Return on Assets	9.81%	7.21%	12.19%	◆ 15.35%	11.58% -15%
Credit & Quality
Total Debt/Equity	0.07×	0.84×	0.11×	◆ 0.00×	0.32× -78%
Interest Coverage	20.55×	8.94×	16.32×	◆ 166.06×	63.77× -68%
Scale — latest FY
Revenue / Total Income	₹9,646 Cr	₹13,980 Cr	₹14,712 Cr	₹4,148 Cr	₹10,947 Cr -12%
Net Income	₹1,184 Cr	₹2,138 Cr	₹2,351 Cr	₹709 Cr	₹1,733 Cr -32%
Total Assets	₹12,370 Cr	₹44,312 Cr	₹20,873 Cr	₹4,969 Cr	₹23,385 Cr -47%
EPS	₹44.98	₹63.92	₹192.51	₹45.16	₹100.53 -55%
Book Value per Share	₹317.85	₹247.86	₹1,156.01	₹258.98	₹554.28 -43%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.